#USA #Orlando #oncology #Canopy #RTM Platform

Canopy's Revolutionary RTM Platform Transforms Patient Care

Recent advancements in oncology patient care were highlighted during an oral presentation at the American Society of Hematology (ASH) Annual Meeting. Canopy, a leader in Enterprise Artificial Intelligence, has introduced significant data that uncovers the efficacy of its Remote Therapeutic Monitoring (RTM) Platform in drastically reducing infection-related hospitalizations and associated healthcare costs. The findings were presented by Dr. Benjamin Derman, highlighting that the platform could lead to nearly $1 million in annual savings per 1,000 patients.

Key Findings from the ASH Annual Meeting

Held in Orlando, Florida, on December 6, 2025, the presentation brought to light several crucial statistics and trends that illustrate how the RTM system operates:

1. Early Detection of Symptoms: Remarkably, 70% of patients had reported symptoms related to infection before experiencing acute events. This suggests that with proactive monitoring, healthcare providers could intervene earlier and manage issues before they escalate.

2. Increased Antibiotic Use: Patients under the RTM program were 20% more likely to receive outpatient antibiotics, which substantially contributed to the reduction of emergency room visits and subsequent hospital stays.

3. Decrease in Hospitalizations: The data revealed a staggering 52% reduction in hospitalization rates due to infections and a 33% decrease in emergency department visits, showcasing the efficacy of the RTM system in improving patient outcomes.

4. Cost Efficiency: Overall, the reduction in the need for acute care linked to infections translated into an estimated annual savings of $977,695 for every 1,000 patients, as per benchmarks from the Agency for Healthcare Research and Quality (AHRQ).

Dr. Derman emphasized the significance of the data, stating, "The timing of symptom reporting seems correlated with the later need for outpatient antibiotic treatment, pointing towards an opportunity for healthcare providers to act sooner and reduce the severity of complications."

Enhancing Patient Insights Through Technology

The rising complexity of cancer therapies necessitates advanced monitoring tools such as Canopy's RTM Platform, which not only provides timely insights into patients' conditions but also helps healthcare practitioners manage the unique risks associated with newer therapies, including bispecific T-cell engagers and CAR T-cell treatments. Dr. James Essell, the Medical Director at Oncology Hematology Care, expressed how integral this technology is for refining patient care.

As the evidence continues to accumulate at ASH regarding the RTM Platform’s effectiveness, it is evident this platform can help reshape the approach to outpatient oncology care. Previous studies presented at ASH have also showcased the positive effects associated with the platform, such as a 37% reduction in treatment discontinuation and improved early detection of toxicities during various therapies.

Canopy is continuously working to explore further enhancements through the use of AI and aims to support clinical interventions at earlier stages of treatment.

Conclusion

With such promising results, Canopy's RTM system stands out as a transformative tool in oncology, with the potential to improve the quality of care delivered to patients while also achieving notable healthcare savings. This innovation acknowledges the pressing need for technologies that provide real-time insights and management strategies for patients undergoing cancer treatment.

For more information on Canopy and their innovative solutions, visit Canopy Care.